Cancer cell adaptation to chemotherapy
Autor: | Silvana Di Palma, Constantinos Yiangou, Ian A. Cree, Sanjay Sharma, Federica Di Nicolantonio, Jeremy Hurren, Sharon Glaysher, Shaw Somers, Augusta Fernando, Alan Lamont, Penny Johnson, Bernard Higgins, Francis G Gabriel, Pauline A. Whitehouse, Stuart Mercer, Tim J. Gulliford, Louise A. Knight, Simon Toh |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2005 |
Předmět: |
Cancer Research
Pathology medicine.medical_specialty Time Factors Paclitaxel medicine.medical_treatment Biopsy Down-Regulation Antineoplastic Agents Irinotecan lcsh:RC254-282 Drug Therapy Surgical oncology Recurrence Cell Line Tumor Neoplasms Genetics medicine Humans Doxorubicin ATP Binding Cassette Transporter Subfamily B Member 1 Epirubicin Cisplatin Chemotherapy business.industry Reverse Transcriptase Polymerase Chain Reaction lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunohistochemistry Up-Regulation Gene Expression Regulation Neoplastic Treatment Outcome Oncology Drug Resistance Neoplasm Cancer cell Cancer research Topotecan Camptothecin Fluorouracil business medicine.drug Research Article |
Zdroj: | BMC Cancer, Vol 5, Iss 1, p 78 (2005) BMC Cancer |
Popis: | Background Tumor resistance to chemotherapy may be present at the beginning of treatment, develop during treatment, or become apparent on re-treatment of the patient. The mechanisms involved are usually inferred from experiments with cell lines, as studies in tumor-derived cells are difficult. Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal selection leads to the resistance of recurrent tumors. Methods Cells derived from 47 tumors of breast, ovarian, esophageal, and colorectal origin and 16 paired esophageal biopsies were exposed to anticancer agents (cisplatin; 5-fluorouracil; epirubicin; doxorubicin; paclitaxel; irinotecan and topotecan) in short-term cell culture (6 days). Real-time quantitative PCR was used to measure up- or down-regulation of 16 different resistance/target genes, and when tissue was available, immunohistochemistry was used to assess the protein levels. Results In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Following exposure to doxorubicin in vitro, 13/14 breast carcinomas and 9/12 ovarian carcinomas showed >2-fold down-regulation of topoisomerase IIα (TOPOIIα). Exposure to topotecan in vitro, resulted in >4-fold down-regulation of TOPOIIα in 6/7 colorectal tumors and 8/10 ovarian tumors. Conclusion This study suggests that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material. The molecular processes used by each tumor appear to be linked to the drug used, but there is also heterogeneity between individual tumors, even those with the same histological type, in the pattern and magnitude of response to the same drugs. Adaptation to chemotherapy may explain why prediction of resistance mechanisms is difficult on the basis of tumor type alone or individual markers, and suggests that more complex predictive methods are required to improve the response rates to chemotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |